ABIONYX Pharma SA (EPA:ABNX)
France · Delayed Price · Currency is EUR 1.604
-0.040 (-2.43%)
Oct 22, 2026, 5:35 PM CEST
ABIONYX Pharma Revenue
In the year 2025, ABIONYX Pharma had annual revenue of 4.06M EUR, down -10.72%. ABIONYX Pharma had revenue of 1.94M in the half year ending December 31, 2025, a decrease of -22.61%. That makes ABIONYX Pharma the 40,237th largest company in the world by revenue and 532nd in France.
Revenue
4.06M
Revenue Growth
-10.72%
P/S Ratio
16.71
Revenue / Employee
82.92K
Employees
49
Market Cap
67.91M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.06M | -488.00K | -10.72% |
| Dec 31, 2024 | 4.55M | -89.00K | -1.92% |
| Dec 31, 2023 | 4.64M | -612.00K | -11.65% |
| Dec 31, 2022 | 5.25M | 4.58M | 678.07% |
| Dec 31, 2021 | 675.00K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cellectis | 55.86M |
| genOway Société anonyme | 24.58M |
| Nicox | 16.77M |
| Fermentalg | 13.20M |
| Innate Pharma | 9.81M |
| Sensorion | 6.16M |
| Transgene | 5.62M |
| Valerio Therapeutics Société anonyme | 5.55M |